Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2012, Article ID 726424, 3 pages
Case Report

Primary Renal Lymphoma: Long-Term Results of Two Patients Treated with a Chemotherapy + Rituximab Protocol

1Department of Urology, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain
2Department of Hematology, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain

Received 4 July 2012; Accepted 22 August 2012

Academic Editors: T. Arkenau and J. I. Mayordomo

Copyright © 2012 F. Vázquez-Alonso et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Primary renal lymphoma (PRL) is a rare disease of which the etiology and pathogenesis remain controversial, and there is currently no standard treatment for it. We present the results of a long-term followup of two patients who were diagnosed with PRL and treated with cyclophosphamide, adriamycin, vincristine, prednisolone and rituximab (CHOP + R) regimen. Both patients reached a complete response, and there is no evidence of recurrence after 4.5- and 5-year followup periods. Based on our experience and other recently published studies, we recommend the combination of CHOP + rituximab as the elective treatment for this disease. To our knowledge, this is the longest followup period with a complete response that has been reported with this modality of treatment.